SCHEMBL2805945

SCHEMBL2805945

COc1cc(C)ccc1S(=O)(=O)N1CCc2c(cnc3[nH]ncc23)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCOLN3 Q8TDD5 1/20 0.48
FGFR1 P11362 1/20 0.44
FGFR2 P21802 1/20 0.44
ALDH1A1 P00352 2/20 0.41
POLB P06746 1/20 0.41
USP2 O75604 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 2/20 0.39
AKR1C3 P42330 2/20 0.38
MAPK1 P28482 1/20 0.37
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
PKM P14618 3/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2802794 0.88 SMN1; SMN2 (0.41) ALDH1A1GAAKMT2ATSHRLMNA
SCHEMBL12316157 0.87 SGK1 (0.35) MCOLN3ALDH1A1USP2GAATSHR
SCHEMBL2804197 0.86 ALDH1A1 (0.46) ALDH1A1GAAKMT2AMAPK1HCRTR1
SCHEMBL2806833 0.85 KMT2A (0.49) MCOLN3FGFR1FGFR2ALDH1A1KMT2A
SCHEMBL2805747 0.85 SGK1 (0.42) FGFR1FGFR2POLBKMT2ALMNA
SCHEMBL12316156 0.85 SGK1 (0.40) ALDH1A1USP2GAAKMT2ATSHR
SCHEMBL2804301 0.84 GAA (0.50) FGFR1FGFR2ALDH1A1POLBUSP2
SCHEMBL2802827 0.83 CYP3A4 (0.56) ALDH1A1POLBUSP2TSHRAKR1C3
SCHEMBL2804811 0.82 PKM (0.44) ALDH1A1POLBGAATSHRPKM
SCHEMBL2805110 0.81 MAPT (0.37) FGFR1FGFR2AKR1C3HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 MCOLN3 2222/4885FGFR1 762/4885FGFR2 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.